Search

Your search keyword '"Godfried, Mieke H."' showing total 10 results
Start Over Author "Godfried, Mieke H." Publication Year Range Last 10 years
10 results on '"Godfried, Mieke H."'

4. sj-docx-1-bji-10.1177_17571774211012455 – Supplemental material for Registration of catheter-related complications in adverse events reporting systems: a major underestimation of the real complication practice

Author

Laan, Bart J, Godfried, Mieke H, and Geerlings, Suzanne E

Subjects
111099 Nursing not elsewhere classified, 111708 Health and Community Services, 111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences
Abstract

Supplemental material, sj-docx-1-bji-10.1177_17571774211012455 for Registration of catheter-related complications in adverse events reporting systems: a major underestimation of the real complication practice by Bart J Laan, Mieke H Godfried and Suzanne E Geerlings in Journal of Infection Prevention

Published
2021
Full Text
View/download PDF

6. Registration of catheter-related complications in adverse events reporting systems: a major underestimation of the real complication practice.

Author

Laan, Bart J, Godfried, Mieke H, and Geerlings, Suzanne E

Subjects
*PUBLIC health laws, *MEDICAL databases, *INFORMATION storage & retrieval systems, *CATHETER-related infections, *URINARY tract infections, *DOCUMENTATION, *URINARY catheters, *CATHETERIZATION complications, *QUALITY assurance, *HOSPITAL wards, *RESEARCH funding, *ADVERSE health care events, *SECONDARY analysis, *BLOODBORNE infections
Abstract

Reporting and learning from preventable adverse events is crucial to improve patient safety. Although physicians should file and analyse adverse events by law in The Netherlands, it is unknown if these reporting systems are sufficiently used in clinical practice. This study is a substudy of the multicenter RICAT trial, a successful quality improvement project to reduce inappropriate use of intravenous and urinary catheters in medical wards in seven hospitals, in which we screened 5696 patients and documented 803 catheter-related complications. We also checked the adverse events reporting systems of these patients and found that only 13 (1.6%) of 803 catheter-related complications were registered. Of the infectious complications only five (10.9%) of 46 catheter-associated bloodstream infections and urinary tract infections were registered. We conclude that the reported complications were a major underestimation of the real complication practice in medical wards in The Netherlands. The RICAT trial is registered at Netherlands Trial Register, trial NL5438. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

7. High treatment uptake in HIV/HCV-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands

Author

Boerekamps, Anne, Newsum, Astrid M., Smit, Colette, Arends, Joop E., Richter, Clemens, Reiss, Peter, Rijnders, Bart J. A., Brinkman, Kees, van der Valk, Marc, Study group members AMC, Geerlings, Suzanne E., Godfried, Mieke H., Goorhuis, Abraham, Hovius, Joppe W. R., van der Meer, Johannes T. M., Kuijpers, Taco W., Nellen, Francisca J. B., van der Poll, Tom, Prins, Jan M., van Vugt, H. J. M., Wiersinga, Willem J., Wit, Ferdinand W. N. M., Graduate School, Global Health, Infectious diseases, AII - Infectious diseases, APH - Quality of Care, General Internal Medicine, APH - Global Health, APH - Aging & Later Life, Center of Experimental and Molecular Medicine, Paediatric Infectious Diseases / Rheumatology / Immunology, ARD - Amsterdam Reproduction and Development, APH - Digital Health, and APH - Personalized Medicine

Subjects
virus diseases
Abstract

The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide HCV treatment uptake among HIV/HCV-coinfected patients. Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA, did not spontaneously clear and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, only data of the most recent treatment episode were included. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved SVR. Of 23,574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men (MSM), 15% people who (formerly) inject drugs and 15% another HIV transmission route) fulfilled the inclusion criteria. Eighty-seven percent (1284/1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124/1471) were cured and in 6% (92/1471) DAA treatment results were pending. Among MSM 83% (844/1022) were cured and in 6% (66/1022) DAA treatment results were pending. Overall 187 patients had never initiated treatment, 14 patients failed DAAs and 54 patients failed a pegylated-interferon-alpha based regimen. Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands are cured (76%) or awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients

Published
2018

9. Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age

Author

Snijdewind, Ingrid J. M., primary, Smit, Colette, additional, Godfried, Mieke H., additional, Bakker, Rachel, additional, Nellen, Jeannine F. J. B., additional, Jaddoe, Vincent W. V., additional, van Leeuwen, Elisabeth, additional, Reiss, Peter, additional, Steegers, Eric A. P., additional, and van der Ende, Marchina E., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results